Q2 2022 Earnings Estimate for Verona Pharma plc (NASDAQ:VRNA) Issued By Jefferies Financial Group

Verona Pharma plc (NASDAQ:VRNAGet Rating) – Analysts at Jefferies Financial Group raised their Q2 2022 earnings per share estimates for shares of Verona Pharma in a report issued on Tuesday, May 3rd. Jefferies Financial Group analyst S. Jeong now expects that the company will post earnings of ($0.35) per share for the quarter, up from their prior forecast of ($0.47). Jefferies Financial Group also issued estimates for Verona Pharma’s Q3 2022 earnings at ($0.37) EPS, Q4 2022 earnings at ($0.34) EPS, FY2022 earnings at ($1.47) EPS, FY2023 earnings at ($0.98) EPS, FY2024 earnings at ($0.70) EPS and FY2026 earnings at $2.38 EPS.

VRNA has been the topic of a number of other research reports. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 target price on shares of Verona Pharma in a research report on Tuesday, January 25th. Zacks Investment Research downgraded Verona Pharma from a “buy” rating to a “hold” rating in a research report on Thursday.

VRNA opened at $4.05 on Friday. The business’s 50-day moving average price is $4.71 and its two-hundred day moving average price is $5.33. Verona Pharma has a 1 year low of $3.66 and a 1 year high of $7.87. The company has a market capitalization of $244.50 million, a price-to-earnings ratio of -3.40 and a beta of 0.67. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.09 and a quick ratio of 5.09.

Verona Pharma (NASDAQ:VRNAGet Rating) last released its quarterly earnings results on Thursday, March 3rd. The company reported ($0.40) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.10.

Several large investors have recently modified their holdings of the company. Marshall Wace LLP bought a new stake in shares of Verona Pharma during the fourth quarter worth approximately $82,000. IPG Investment Advisors LLC bought a new stake in shares of Verona Pharma during the fourth quarter worth approximately $80,000. Geode Capital Management LLC boosted its holdings in shares of Verona Pharma by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 13,273 shares of the company’s stock worth $89,000 after acquiring an additional 2,566 shares during the period. D.A. Davidson & CO. boosted its holdings in shares of Verona Pharma by 20.0% during the fourth quarter. D.A. Davidson & CO. now owns 48,000 shares of the company’s stock worth $323,000 after acquiring an additional 8,000 shares during the period. Finally, Lindbrook Capital LLC bought a new stake in shares of Verona Pharma in the fourth quarter valued at approximately $67,000. Institutional investors own 61.19% of the company’s stock.

In other Verona Pharma news, insider Kathleen A. Rickard sold 59,720 shares of the business’s stock in a transaction that occurred on Monday, April 11th. The stock was sold at an average price of $0.54, for a total transaction of $32,248.80. Following the transaction, the insider now owns 2,546,408 shares of the company’s stock, valued at $1,375,060.32. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Kathleen A. Rickard sold 112,800 shares of the business’s stock in a transaction that occurred on Friday, April 8th. The stock was sold at an average price of $0.59, for a total value of $66,552.00. Following the transaction, the insider now directly owns 2,606,128 shares in the company, valued at approximately $1,537,615.52. The disclosure for this sale can be found here. In the last three months, insiders have sold 246,688 shares of company stock worth $135,597. Company insiders own 3.90% of the company’s stock.

Verona Pharma Company Profile (Get Rating)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Further Reading

Earnings History and Estimates for Verona Pharma (NASDAQ:VRNA)

Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter.